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Abstract
Leukotrienes (LTs) are lipid mediators involved in several inflammatory disorders. We investigated the LT pathway in human
T-lymphotropic virus type 1 (HTLV-1) infection by evaluating LT levels in HTLV-1-infected patients classified according to the
clinical status as asymptomatic carriers (HACs) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)
patients. Bioactive LTB4 and CysLTs were both increased in the plasma and in the supernatant of peripheral blood
mononuclear cell cultures of HTLV-1-infected when compared to non-infected. Interestingly, CysLT concentrations were
increased in HAM/TSP patients. Also, the concentration of plasma LTB4 and LTC4 positively correlated with the HTLV-1
proviral load in HTLV-1-infected individuals. The gene expression levels of LT receptors were differentially modulated in
CD4+ and CD8+ T cells of HTLV-1-infected patients. Analysis of the overall plasma signature of immune mediators
demonstrated that LT and chemokine amounts were elevated during HTLV-1 infection. Importantly, in addition to CysLTs,
IP-10 was also identified as a biomarker for HAM/TSP activity. These data suggest that LTs are likely to be associated with
HTLV-1 infection and HAM/TSP development, suggesting their putative use for clinical monitoring.
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Introduction
Human T-lymphotropic virus type 1 (HTLV-1), a complex
retrovirus, is the causal agent of adult T cell leukemia (ATL),
HTLV-1-associated myelopathy/tropical spastic paraparesis
(HAM/TSP) and other inflammatory disorders that develop after
a variable period of latency ranging between months and decades
[1,2]. Although the majority of HTLV-1-infected individuals
remain asymptomatic carriers (HACs), the lifetime risk of
developing HTLV-1-associated diseases may be close to 10%,
and the incidence of HAM/TSP ranges from 0.3% to 4% [3].
HAM/TSP is a neuroinflammatory disease characterized by a
chronic progressive myelopathy with infiltrating mononuclear cells
in the areas of demyelination and axonal dystrophy [4,5]. It is not
clear how HTLV-1 causes neurological damage, but spontaneous
T cell proliferation and proinflammatory responses characterized
by elevated ex vivo production of interferon (IFN)-c and tumor
necrosis factor (TNF)-a by peripheral blood mononuclear cells
(PBMCs) are associated with HAM/TSP [6,7]. In addition,
patients with HAM/TSP display an increased proviral burden
when compared to HACs, and high proviral loads have been
associated with rapid disease progression [8–10]. Thus, few disease
markers and prognostic predictors have been described for HAM/
TSP.
Leukotrienes (LTs) are bioactive lipid mediators involved with
inflammatory conditions [11] that may represent candidate
biomarkers for HAM/TSP. Biosynthesis of LTs is triggered by
stimuli such as antigen, cytokines, microorganisms and immune
complexes [12]. Just after stimulation, arachidonic acid (AA) that
is liberated from cellular membrane phospholipids through the
action of phospholipase A2 (PLA2) is oxidized by 5-lipoxygenase
(5-LO) in combination with 5-LO-activating protein (FLAP) to
generate the leukotriene A4 (LTA4). The downstream enzymes
LTA4 hydrolase (LTA4H) and LTC4 synthase (LTC4S) give rise to
leukotriene B4 (LTB4) and leukotriene C4 (LTC4). LTC4 is further
converted to LTD4 and LTE4, which are collectively termed
cysteinyl leukotrienes (CysLTs) respectively. LTB4 and CysLTs
signal through distinct cell surface receptors named BLT1 and
BLT2 and CysLT1 and CysLT2, respectively [13]. Functionally,
LTB4 is recognized as a potent leukocyte chemoattractant that
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also displays leukocyte activating functions, whereas the CysLT
are better known for leading to airway constriction, increased
vascular permeability, mucus secretion and cell trafficking [14]. In
addition, LTs have been shown to improve the host defense
against pathogens [15–18].
Considering the importance of LTs as powerful mediators of
inflammation, the present study was undertaken to test the
hypothesis that HTLV-1 infection leads to an exacerbation of the
5-LO products formation and LT signaling in patients with
HAM/TSP. We examined LT concentrations in plasma, the
ability of PBMCs to produce LTs and LT receptor expression in
lymphocytes from HTLV-1 patients. We also investigated the
overall plasma LT, chemokine and cytokine signatures of HACs
and HAM/TSP patients. Moreover, we investigated the correla-
tions between LTs, chemokines and cytokines in HTLV-1-infected
individuals and the capacity of LTs to modulate cytokine
production. Our results demonstrate for the first time that LTs
are upregulated during HTLV-1 infection, suggesting a role for
LTs in HAM/TSP pathogenesis and presenting them as potential
biomarkers for monitoring HAM/TSP development.
Results
CysLT is Upregulated in HTLV-1-associated
Neuroinflammatory Disease
LTs have been shown to function as inflammatory mediators
[11]. To investigate whether HAM/TSP disease is characterized
by elevated levels of LTs, we measured the amount of these
mediators in the plasma of HTLV-1 patients. LTB4 was increased
in the plasma of HACs and HAM/TSP patients when compared
to that of NI donors; however, no difference was observed in LTB4
levels between HACs and HAM/TSP patients (Figure 1A).
Interestingly, HACs and HAM/TSP patients displayed increased
amounts of CysLTs when compared with NI donors, but CysLT
amounts were higher in the plasma of HAM/TSP patients than in
the plasma of HACs (Figure 1B). Thus, although HTLV-1 induces
increased concentrations of LTs in the plasma of both HACs and
HAM/TSP patients, these results associate increased CysLT
concentrations with HAM/TSP. In addition, we explored the
correlation between HTLV-1 proviral load and plasma LTB4
(Figure 1C) or CysLTs (Figure 1D) and found a positive
correlation. Thus, in infected persons, the plasma LTs are
associated with the HTLV-1 proviral load in PBMCs.
HTLV-1 Enhances LT Generation
HTLV-1-induced LT generation was examined in PBMCs of
NI donors. We found increased production of LTB4 (Figure 2A)
and LTC4 (Figure 2B) when cells were challenged with cell-free
virus. Next, because we found increased levels of LTs in the
plasma of HTLV-1 patients, we measured LT generation by
PBMCs from HTLV-1 patients. We observed increased produc-
tion of LTB4 by cells from HACs and HAM/TSP patients when
compared to those from NI donors, with the highest amount of
LTB4 in the supernatant of cells from HACs (Figure 2C).
Moreover, as expected, the generation of CysLTs was increased
in PBMCs from HACs and HAM/TSP patients when compared
to those from NI donors, with the highest amount of CysLTs in
cells from HAM/TSP patients (Figure 2D). Next, we assessed 5-
LO and LTC4 synthase expression in PBMCs. Our results
demonstrated that cells from HAM/TSP patients expressed
higher levels of 5-LO than cells from NI donors or HACs
(Figure 2E); however, no differences in the expression of LTC4
synthase were observed between the groups (Figure 2F).
Lymphocytes from HTLV-1 Patients have Altered LT
Receptor Gene Expression
We next analyzed the gene expression of LT receptors by
detecting BLT1 and CysLT1 expression in both CD4
+ and CD8+
T cells (Figure 3). In CD4+ T cells, BLT1 expression was increased
only in HAM/TSP patients than in NI donors (Figure 3A) but
CysLT1 was expressed at higher amounts in HACs and HAM/
TSP patients than in NI donors (Figure 3B). Analysis of CD8+ T
cells showed no differences in BLT1 gene expression among all of
the groups (Figure 3C), whereas decreased CysLT1 gene
expression was detected in HAC and HAM/TSP patient CD8+
T cells when compared to NI donor CD8+ T cells (Figure 3D).
Overall Plasma Signatures of LTs, Chemokines and
Cytokines in HTLV-1 Infection
We next sought to characterize the immune and inflammatory
mediators in the plasma of NI donors to allow for further
comparative analysis of HACs and HAM/TSP patients. We
assessed the overall LT, chemokine and cytokine signatures by
categorizing volunteers as ‘‘low-’’ or ‘‘high-’’ mediator producers
to minimize the impact of individual concentrations on the final
analysis and to make the data more homogeneous. The global
median index of each mediator was calculated (CysLTs = 438.9;
LTB4 = 402.6; IP-10 = 91.4; MCP-1 = 75.8; MIP1-a= 41.2; IL-
8 = 0; IL-17 = 0; IL-23 = 0; IL-1 = 0; IL-4 = 0; IL-10 = 0; TNF-
a= 0; IL-12 = 0; IFN-c= 0; IL-6 = 0; IL-5 = 0; GM-CSF = 9.2; IL-
13 = 26.2) (data not shown), and based on these values, each
volunteer was classified as a low- (%) or high (&)-mediator
producer (upper panels in Figures 4 A, B, C). An assembly of the
frequency of high-mediator producers among NI donors in
ascendant fashion is shown in Figure 4A. The mediator signature
curves of NI donors were used as a reference to identify changes in
the overall mediator signatures of HACs and HAM/TSP patients.
Analysis of the HAC signatures demonstrated that LTs, the
majority of chemokines (MCP-1, IL-8 and MIP1-a) and some
cytokines (IL-17, IL-23, IL-4, TNF-a and IL-12) are increased
when compared to the values observed in NI donors (Figure 4B).
We also examined the signatures of HAM/TSP patients
(Figure 4C) and found that LTs and chemokines (MCP-1 and
IP-10) were increased, and in contrast to our findings in HACs,
cytokines were decreased when compared to the values observed
in NI donors. Additionally, high producers of CysLTs and IP-10
were more frequent in HAM/TSP group than in HACs. In
contrast, the frequency of high cytokine producers was lower in
HAM/TSP patients than in HACs. Thus, our findings showed
that LTs and chemokines are the prominent mediators in HACs
and HAM/TSP patients.
Association between Immune and Inflammatory
Mediators in HTLV-1 Infection
The differences in the concentrations of LTs, chemokines and
cytokines between HACs and HAM patients prompted us to
investigate the correlation between the concentrations of media-
tors in each group. The analysis of the HAC group demonstrated
positive correlation between the concentrations of CysLTs with
the concentrations of LTB4 and IL-13 (Figure 5A). In contrast to
our findings in HACs, CysLT concentrations were not correlated
with the amounts of other mediators, but LTB4 concentrations
were positively correlated with the levels of some chemokines,
including MCP-1 and IP-10, and cytokines, including IL-17, IL-23
and IL-10 in HAM/TSP patients (Figure 5B). Meanwhile,
although no specific pattern associated with any kind of immune
or inflammatory response was observed, the expression levels of
Leukotriene Pathway in HTLV-1 Infection
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several chemokines and cytokines were correlated in HACs and
HAM/TSP patients (Figure 5).
Discussion
The participation of LTs in several infections [19,20] and
inflammatory disorders [21,22] has long been appreciated;
however, the involvement of these lipid mediators in HTLV-1
infection and HAM/TSP development has not been studied
previously. Here, we report for the first time that HTLV-1
infection dysregulates the LT pathway. Our results demonstrate
increased LTB4 and CysLT plasma concentrations in HTLV-1
patients, suggesting a role for LTs in several HTLV-1-associated
inflammatory diseases. Furthermore, a key finding in our study
was the association between plasma CysLT concentrations and
HAM/TSP. The concentration of plasma CysLTs was increased
more than 3-fold in HAM/TSP patients when compared to
HACs. Studies have detected LTs in the central nervous system of
patients with autoimmune diseases [23] and infectious diseases
[24,25] and have suggested a potential pathophysiological role for
these molecules. Specifically, the inhibition of 5-LO activity during
experimental demyelination attenuates neuroinflammation and
axonal damage [26]. Together, these observations are consistent
Figure 1. Leukotrienes are increased in the plasma of HTLV-1-infected subjects and correlate with the proviral load. LTB4 (A) and
CysLTs (B) were measured by EIA after sample purifications on Waters C18 Sep-Pak cartridges. Plasma from non-infected healthy donors (NI), HTLV-1
asymptomatic carriers (HAC) and HAM/TSP subjects (HAM) were used. (C, D) A correlation is shown between the plasma levels of LTB4 (C), CysLTs (D)
and the DNA proviral load in peripheral blood mononuclear cells of HTLV-1-infected individuals (HAC and HAM/TSP) using Pearson rank correlation
test. The data are presented as means 6 SEM. *p,0.05, compared with control; #p,0.05, compared with HAC (one-way ANOVA). Statistically
significant correlations at p,0.05 are displayed in the graphs along with Pearson’s coefficient (r).
doi:10.1371/journal.pone.0051873.g001
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Figure 2. HTLV-1 primes cells for leukotriene generation. (A–D) 106 peripheral blood mononuclear cells were cultured for 48 hours and then
treated for 30 min with A23187 (0.5 mM) before detection of LTB4 (A, C) and LTC4 (B, D) by EIA (n = 7 per group). (A, B) Cells from non-infected healthy
donors were seeded alone (unstimulated) or in the presence of cell-free HTLV-1 (HTLV-1 virions). (C, D) Cells from non-infected healthy donors (NI),
Leukotriene Pathway in HTLV-1 Infection
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with our results demonstrating that HAM/TSP patients display
enhanced CysLT production, suggesting that these mediators
contribute to HAM/TSP pathogenesis. As there is no effective
therapy for HAM/TSP [27], CysLT signaling may represent a
new therapeutic target. Although many investigators have
concentrated their efforts on the discovery of HAM/TSP markers,
previous studies have relied on ex vivo culture, and few
associations have been established in vivo [28,29]. Thus, our
work extends to the knowledge of in vivo HAM/TSP markers by
presenting CysLTs as a putative biomarker of HAM/TSP.
Therefore, we next tested the hypothesis that HTLV-1 proviral
load is correlated with the concentration of plasma LTs. Using
Pearson’s correlation, we observed a positive correlation between
LTB4 or CysLTs and proviral load indicating that concentrations
of LTs in plasma of infected individuals reflect proviral load.
However, in the present study, our data did not demonstrate a
strong association between LTs and disease activity or even
clinical progression in HAM/TSP patients. In this pioneering
investigation, we explored the complex pro-inflammatory network
underlying the immunological profile of HLTV infected patients
to find potential biomarkers of disease activity or even prognostic
markers for monitoring purposes. We believe that LTs could be
putative immunological biomarkers that could serve as prognostic
markers or could be associated with disease activity. It is important
to mention that the present investigation should be considered the
first step toward the discovery of LT biomarkers for HLTV
infection, as further studies will be necessary to validate this
hypothesis.
HTLV-1 asymptomatic carriers (HAC) and HAM/TSP patients (HAM) were cultured. (E,F) Quantitative PCR (qPCR) was performed to detect 5-LO (E) and
LTC4 synthase (F). The relative expression levels of these genes were determined in PBMCs from NI donors, HACs and HAM/TSP patients (n = 15 per
group). Gene expression levels were normalized to the expression level of GAPDH mRNA in the same real-time PCR reaction. The data are presented
as means 6 SEM. *p,0.05, compared with unstimulated samples or NI donors; #p,0.05, compared with HACs (t-test or one-way ANOVA as
appropriate).
doi:10.1371/journal.pone.0051873.g002
Figure 3. Leukotriene receptor mRNA expression in lymphocytes of HTLV-1 patients. Quantitative PCR (qPCR) was performed for BLT1 (A,
C) and CysLT1 (B, D), and their relative expression levels were determined in CD4
+ (A, B) and CD8+ (C, D) T cells from twenty non-infected healthy
donors (NI), twenty asymptomatic carriers (HAC) and seventeen HAM/TSP patients (HAM). Gene expression levels were normalized to the gene
expression levels of ACTB, GAPDH, B2M and RPL13a for CD4+ T cells and of ACTB for CD8+ T cells in the same real-time PCR reaction. The data are
presented as means 6 SEM. *p,0.05, compared with NI donors; #p,0.05, compared with HACs (one-way ANOVA).
doi:10.1371/journal.pone.0051873.g003
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LTs are produced primarily by neutrophils, eosinophils, mast
cells and monocytes/macrophages [30]. Among PBMCs, it is
assumed that monocytes are largely responsible for LT generation.
Moreover, B cells express 5-LO but do not synthesize LTs upon
A23187 stimulation [31]. Notably, we found that cell-free viral
particles induce LT generation by PBMCs after A23187
stimulation, suggesting that monocytes are a significant source of
LTs during HTLV-1 infection. This also suggests that LT
production is increased in the central nervous system of HAM/
TSP patients because infiltrating monocytes are found in the areas
of demyelination [4] and may be stimulated by the virus to release
lipid mediators. Importantly, HTLV-1 and HTLV-1-Tax antigen
induce another lipid mediator, PGE2 [32], demonstrating that
HTLV-1 regulates both the 5-LO and the cyclooxygenase
pathway of the AA cascade. Moreover, LTC4 generation by
PBMCs supports elevated concentrations of plasma CysLTs in
HAM/TSP patients. However, despite the low number of HTLV-
1 virions in vivo, a DNA insertion analysis showed that the virions
can induce the production of LTs in PBMCs in vitro without
infecting these cells (data not shown). On the other hand, LTs are
involved in the control of host defense, including defense against
HIV [33,34]; thus, the decreased LTB4 generation observed in the
PBMCs of HAM/TSP patients when compared to HACs may not
represent a good method for controlling the high HTLV-1 set
points seen in HAM/TSP patients. In addition, it was interesting
to note the lack of correlation between 5-LO and LTC4S gene
expression and LT generation by human PBMCs. Despite this
dissociation between changes in 5-LO mRNA levels and protein
expression, which has been reported previously [35,36], increased
5-LO mRNA expression indicates a positive regulation of the LT
pathway as evidenced by the increased mRNA expression of 5-LO
in HAM/TSP PBMCs.
The upregulation of LT receptors has been noted previously in
experimental neuroinflammatory disease and is thought to be
involved in the pathogenesis of this disease [37,38]. It is
noteworthy that LT receptor expression has been detected in
both CD4+ and CD8+ T cells [12]. These cells are found in
inflamed areas in HAM/TSP patients. Thus, we hypothesized that
LT receptor expression may be increased in T cells in HAM/TSP
patients. Our data demonstrate that gene expression of LT
receptors is modulated by HTLV-1 infection. Specifically, BLT1
was upregulated in CD4+ T cells from HAM/TSP patients.
Meanwhile, CysLT1 was upregulated in CD4
+ T cells but
downregulated in CD8+ T cells of HACs and HAM/TSP patients.
In animal models, deletion of BLT1 [39] and inhibition of CysLT1
[40] signaling can suppress the recruitment of inflammatory cells
into the central nervous system and thus inhibit experimental
autoimmune encephalomyelitis. In this regard, we speculate that
high LT amounts and high LT receptor expression levels in CD4+
T cells may bias the host toward cellular infiltration of inflamed
tissues, worsening the HAM/TSP disease. Moreover, as HTLV-1
preferentially affects CD4+ T cells, the migration of non-infected
CD4+ T cells to inflamed sites containing HTLV-1-infected
lymphocytes could facilitate cell-cell contact and consequently the
spread of infection.
Studying the immunological response to HTLV-1 infection is
important for the understanding of HAM/TSP pathogenesis.
Others have shown that CXCL9 [41], CXCL10 [42], CCL22
[43], IP-10 [28], sCD30 [28] and IFN-c [28] are increased in the
systemic circulation of HTLV-1-infected individuals. We hypoth-
esized that dysregulation of the immune system is likely to be
involved in the pathogenesis of HLTV-1 infection and that the
clinical presentation of HAM/TSP may result from multifactorial
immunological mechanisms. Impairment in the cytokine network
has been found to be one of the determining factors in several
human diseases. Because conventional strategies may not be
suitable to capture minor changes in the immunological profile
and because of the wide range of chemokines/cytokines/LTs, in
this study, we employed an alternative strategy to assess the
biomarker signature and to describe the dominant profiles
associated with asymptomatic presentation and HAM/TSP
caused by chronic HTLV-1 infection. This panoramic overview
offers additional insight into the immunological events that are
relevant for clinical studies of HTLV-1 infection. This approach
may allow for a better understanding of the immunological
parameters that control disease outcome and provide useful tool
for prognostic monitoring. We therefore examined the concen-
trations of several chemokines and cytokines in the plasma of our
cohort to further establish a signature curve for LTs, chemokines
and cytokines. Using a signature curve of non-infected individuals
as a reference, we demonstrated that LTs and chemokines are
increased in the plasma of both HACs and HAM/TSP patients.
The signature curves both confirm CysLT and identify IP-10 as
biomarkers of HAM/TSP. The Th1-associated chemokine IP-10
belongs to the CXC chemokine superfamily. IP-10 has been
shown to be a potential marker of inflammation and diseases [43–
45] including HAM/TSP [28]. Furthermore, our results show that
although the plasma concentrations of some cytokines are
increased in HACs, the majority of the analyzed cytokines are
decreased in the plasma of HAM/TSP patients. The low levels of
these cytokines observed in HAM/TSP patients may reflect the
attenuated inflammatory response observed in the central nervous
system after a long period of HAM/TSP manifestation [46]. In
contrast to these decreased cytokine levels, however, our work
clearly demonstrates some plasma mediators of inflammation
remain elevated even after a long period of disease manifestation.
In addition, as a trigger for positive feedback regulation, LTs,
chemokines and cytokines have been shown to influence the
production of each other [16,18,47,48]. Supporting these findings,
we have shown positive correlations between plasma LT,
chemokine and cytokine concentrations but in the absence of a
singular pattern of immune response. Importantly, CysLTs are
increased in HAM/TSP patients, but no positive correlation was
detected between CysLT levels and the concentrations of other
mediators, presenting this family of lipid mediators as an
independent biomarker of HAM/TSP.
Figure 4. Signature curves of high biomarker producers during HTLV-1 infection. (A) Representative scattergraphs were used to establish
the concept of low biomarker producers (white) and high biomarker producers (black). The results from all groups studied (non-infected donors,
HACs and HAM/TSP patients) were assembled to calculate the global median for each biomarker. Low biomarker producers were defined as having
values lower than the global median, whereas high biomarker producers were defined as having values greater than or equal to the global median
cut-off. Data from 3 of 18 molecules analyzed are shown. (B–D) The diagrams were plotted using the global median index of plasma biomarkers
(measured by ELISA) as the cut-off to identify each volunteer as a low (%) or high (&) producer. The ascendant frequency of high producers found in
the NI group was established as a reference curve (–%–) to identify changes in the overall biomarker signature of the other groups. Significant
differences were defined as a shift to a distinct 25% quartile interval between the studied groups. *, significantly different values compared with NI
donors; #, significantly different values compared with HACs. NI – non-infected healthy donors; HAC – HTLV-1 asymptomatic carriers; HAM – HAM/
TSP subjects.
doi:10.1371/journal.pone.0051873.g004
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Figure 5. Correlation of plasma biomarkers in HTLV-1 infection. Samples from HTLV-1-infected subjects were used to detect leukotrienes,
chemokines and cytokines by ELISA. A correlation analysis was performed to analyze biomarkers levels. The results of a non-parametric Spearman’s
test and ‘r’ index are provided in the figure. Filled squares indicate positive correlations. HAC – HTLV-1 asymptomatic carriers; HAM – HAM/TSP
subjects.
doi:10.1371/journal.pone.0051873.g005
Leukotriene Pathway in HTLV-1 Infection
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In this report, we demonstrate that HTLV-1 dysregulates the
LT pathway. This finding has important implications for the
understanding of HAM/TSP. First, CysLTs could be used as a
biomarker for HAM/TSP development. Second, the fact that LTs
are mediators of inflammation suggests that the LT pathway might
be involved in HAM/TSP pathogenesis. Therefore, further
experiments will be required to elucidate a potentially pathogenic
function of LTs in HAM/TSP. Moreover, it will be interesting to
determine whether drugs targeting the LT pathway ameliorate
HAM/TSP symptoms.
Patients, Materials and Methods
Study Population
The study subjects were classified as asymptomatic HTLV-1
carriers or HAM/TSP patients in accordance with the criteria
proposed by the World Health Organization. Non-infected (NI)
healthy volunteers were included as a control (Table 1). Biological
specimens were obtained from HTLV-1 patients from the clinical
cohort of the Neurology Department of Ribeira˜o Preto University
Hospital, Brazil. Diagnosis of HTLV-1 infection was established
by enzyme-linked immunosorbent assay (ELISA) (rp21e-enhanced
EIA; Cambridge Biotech Corp.) and confirmed by PCR (tax and
LTR regions). Subjects with HAM/TSP were selected from
among a heterogeneous disease progression group. Individuals
receiving therapies were excluded. All procedures were approved
by the Ethical Committee of the University Hospital, School of
Medicine of Ribeira˜o Preto, University of Sa˜o Paulo (process
number 1108/2008), and all subjects provided written informed
consent.
Isolation of Blood Leukocytes
After separation of plasma from the heparinized venous blood,
PBMCs were isolated using Ficoll-Paque (GE Healthcare) density
gradient centrifugation. To isolate lymphocytes from PBMCs,
magnetic beads conjugated with anti-CD4 or anti-CD8 antibodies
(Mini-Macs Micro-Beads, Miltenyi Biotec) were used to separate
CD4+ and CD8+ T cells by positive selection using the
manufacturer’s protocol. Phenotypic analysis performed by flow
cytometry (BD-FACSCanto) using anti-CD4-FITC, anti-CD8-
FITC and anti-CD3-PE antibodies (BD Biosciences) demonstrated
a minimum of 80% purity of CD4+ and CD8+ lymphocytes. A
hemocytometer chamber was used to obtain absolute cell counts,
and cell viability was determined by trypan blue exclusion.
HTLV-1 Proviral load
HTLV-1 proviral load was quantified as previously described
[49]. Genomic DNA samples isolated from peripheral blood of the
HTLV-1 infected individuals were used to perform quantitative
RT-PCR with the SYBR Green system (Applied Biosystems). The
single-sample reactions for human b-actin and HTLV-1 tax were
performed in duplicate on the same plate. The HTLV-1 proviral
load was calculated using the following equation: average of tax/
average of b-actin626105. The values obtained were Log10
transformed for the correlation analysis.
Detection of Leukotriene Pathway Transcripts
Total RNA was extracted from PBMCs and lymphocytes with
TRIzol (Invitrogen) according to the manufacturer’s instructions,
and reverse transcription was carried out with 2 mg of total cellular
RNA using a High-Capacity cDNA Reverse Transcription kit
(Applied Biosystems). Thereafter, quantitative RT-PCR was
performed using ABI 7500 Sequence Detection (Applied Biosys-
tems). The reaction was performed in duplicate using TaqMan
assay reagents (Applied Biosystems) (product reference for 5-LO:
Hs_00386528_m1; LTC4 synthase: Hs_00168529_m1; BLT1:
Hs_00175124_m1; CysLT1: Hs_00929113_m1) and analyzed
using 7500 System SDS software. The relative mRNA expression
was determined using the DDCT method. Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH: 4310884-E) was used as an
internal control for PBMCs. The geometric means of the values
obtained for b-actin (ACTB: 4326315E), GAPDH, b2 micro-
globulin (B2M: 4333766-0710013) and ribosomal protein L13a
(RPL13a: 185720330-7) were used as internal controls for CD4+ T
cells, and ACTB was used as an internal control for CD8+ T cells.
Production of Cell-free Virus
The human T cell line MT-2 was used as a source of HTLV-1
producing cells. For preparation of cell-free HTLV-I, cells were
seeded at 56105/mL and incubated at 37uC in a humidified CO2
atmosphere for 2 days in RPMI supplemented with 10% FBS. The
supernatants were passed through a 0.45-mm filter (Millipore) to
remove cells and debris, and the virions were concentrated 10
times by ultracentrifugation for 2 hours at 100,000 g. The pellet
containing virus particles was resuspended in RPMI and
quantified before being subjected to HTLV-1 p19 ELISA
(ZeptoMetrix).
Stimulation and Culture of Cells
We plated PBMCs (106/well) in forty eight-well plates and
maintained them overnight at 37uC and 5% CO2. The cells were
provided with fresh RPMI 1640 containing 5% AB human serum
(Sigma) and 100 U/mL penicillin and cultured for an additional
48 hours. For analysis of the effects of cell-free HTLV-1, cell
cultures from healthy donors were challenged with 10 ng of virions
particles (p19 equivalent) prior additional culture. For leukotriene
detection, the supernatants were removed, and the cells were
resuspended in HBSS containing Ca2+ and Mg2+ and stimulated
Table 1. Demographical and Clinical Characteristics of the Study Groups.
Group Number Age, mean years (± SD) Sex (M/F)a
Proviral load mean/105 cell (±
SD)
First reported symptoms, mean
years (± SD)
Non-infected 31 45.7 (612.2) 9/22 N/Ab N/A
HACc 26 42.9 (612.9) 11/15 2,105.4 (62,312.2) N/A
HAM/TSPd 19 54.9 (69.1) 4/15 6,180.9 (63,544.6) 13 (69.7)
Note. aM/F: male/female;
bN/A: not applicable;
cHAC: HTLV-1 asymptomatic carriers;
dHAM/TSP: HTLV-1 associated myelopathy/tropical spastic paraparesis.
doi:10.1371/journal.pone.0051873.t001
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for 30 minutes with 0.5 mM of the calcium ionophore A23187
(Sigma), and then, reactions were stopped using ice.
Measurement of Leukotrienes, Chemokines and
Cytokines
A specific enzyme immunoassay (Cayman) was used to quantify
LTB4 and LTC4 in cell-free supernatants and LTB4 and CysLT in
plasma per the manufacturer’s instructions. For plasma measure-
ments, samples stored at 270uC were purified on Waters C18
Sep-Pak cartridges (Waters Associates) prior to performing the
assay. Moreover, the cell-free supernatants were tested for IP-10
and TNF-a, and the plasma samples were tested for MCP-1,
MIP1-a, IP-10, IL-8, IL-5, IL-4, IL-13, IL-1, IL-6, GM-CSF,
TNF-a, IL-12, IFN-c, and IL-10 using a Duoset ELISA
Development kit (R&D Systems) and for IL-17 and IL-23 using
an OptEIA ELISA kit (BD Bioscience) in accordance with the
manufacturer’s instructions. The reactions were performed in 96-
well ELISA plates (Corning), and the optical densities were
determined at 450 nm using a microplate reader. The cytokine
concentration in each sample was estimated by interpolation of
sample optical densities with the cytokine standard using a four-
parameter curve-fitting program.
Leukotriene, Chemokine and Cytokine Signature Analysis
A method for identifying low and high producers of mediators
by analyzing cytokine profiles was previously reported by Luiza-
Silva et al. [50]. The concentrations of LTs, chemokines and
cytokines (pg/mL) were assembled to calculate the global median
index ([values of NI donors+HACs+HAM/TSP patients]/number
of samples), and plasma samples were characterized as low- or
high-mediator producers. Low-mediator producers were defined
as having values lower than the global median, whereas high-
mediator producers were defined as having values greater than or
equal to the global median cut-off. The percentage of high
producers was calculated for each analyzed molecule, and the
ascendant frequency of the non-infected group was used as the
reference curve to identify changes in the overall mediator patterns
from all the groups.
Statistics
The data are presented as means 6 SEM of values determined
from the indicated number of samples. The data were analyzed by
Student’s t-tests or ANOVA with Bonferroni’s post-test as
appropriate to identify significant differences between group
means using GraphPad Prism version 5 (GraphPad Software).
Spearman’s correlation test was performed to assess the
association between the levels (pg/mL) of LTs, chemokines and
cytokines while Person’s test was used to analyze the association of
LTs and the HTLV-1 proviral load. In all cases, statistical
significance was defined as p#0.05. The cytokine signatures
analyses were performed using the non-infected signature as the
reference curve, and differences were considered significant when
the values fell outside of the quartile of the reference signature.
The use of the 50th percentile as the limit to identify relevant
differences in the chemokine/cytokine/LT signatures between the
groups has been adapted from a pioneering study by Luiza-Silva
et al. [50]. This approach has been shown to be relevant to detect,
with high sensitivity, putative minor changes in the cytokine
signatures that are not detectable by conventional statistical
approaches.
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